上海凯宝(300039) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥459,387,490.40, representing a 33.61% increase compared to ¥343,817,802.76 in the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥80,178,876.36, a 39.11% increase from ¥57,636,350.93 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥74,483,881.60, reflecting a 30.24% increase compared to ¥57,190,694.89 in the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.0767, up 39.20% from ¥0.0551 in the same quarter last year[5] - Total operating revenue for Q1 2023 reached ¥459,387,490.40, an increase of 33.7% compared to ¥343,817,802.76 in the same period last year[22] - Net profit for Q1 2023 was ¥80,118,147.25, representing a 40.2% increase from ¥57,142,663.02 in Q1 2022[23] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥353,887,256.07, compared to ¥165,979,475.93 in Q1 2022, indicating a significant increase of about 113.1%[24] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥4,757,637,196.49, an increase of 11.70% from ¥4,259,271,286.92 at the end of the previous year[5] - Total liabilities reached ¥642,779,893.90, compared to ¥498,240,511.29 at the start of the year, an increase of 29.0%[20] - The company's equity attributable to shareholders rose to ¥4,115,640,086.51 from ¥3,761,752,830.44, an increase of 9.4%[20] Cash Flow - The company's cash flow from operating activities for Q1 2023 was ¥79,310,976.85, down 8.90% from ¥87,056,121.17 in the same period last year[5] - Cash inflows from operating activities totaled ¥485,001,700.80 in Q1 2023, compared to ¥427,893,178.34 in Q1 2022, marking an increase of about 13.3%[27] - The net cash flow from operating activities for Q1 2023 was ¥79,310,976.85, a decrease from ¥87,056,121.17 in Q1 2022, representing a decline of approximately 8.0%[27] - The net cash flow from investment activities increased by 350.96% compared to the same period last year, primarily due to a reduction in the purchase of financial products[13] - The net cash flow from financing activities decreased by 100.00% compared to the same period last year, mainly due to a reduction in cash inflows from financing activities[13] - The net increase in cash and cash equivalents grew by 2115.61% compared to the same period last year, attributed to a decrease in cash outflows from investment activities[13] - The total cash and cash equivalents at the end of Q1 2023 reached ¥582,156,672.45, up from ¥287,816,363.17 at the end of Q1 2022, reflecting an increase of approximately 102.2%[27] Research and Development - Research and development expenses increased by 140.34% year-on-year, indicating a significant investment in new product development[11] - Research and development expenses increased significantly to ¥24,076,351.54, compared to ¥10,017,656.02 in the previous year, reflecting a growth of 140.1%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 79,143, with no preferred shareholders having restored voting rights[13] - The top three shareholders hold a combined 38.93% of the total shares, with Mu Jingwei holding 16.06%, Zhang Yanqi holding 15.37%, and Xinxiang Kaiyi Industrial Co., Ltd. holding 7.50%[13] - The total number of restricted shares at the end of the period is 129,152,731, all of which are subject to executive lock-up[16] Subsidiaries - The company established two new subsidiaries: Henan Yishen Pharmaceutical Chemical Co., Ltd. with a registered capital of RMB 20 million and Henan Kaibao Pharmaceutical Co., Ltd. with a registered capital of RMB 1 million[17] - The company holds 90% of the shares in Henan Yishen Pharmaceutical Chemical Co., Ltd., which was registered on February 28, 2023[17] - The company holds 100% of the shares in Henan Kaibao Pharmaceutical Co., Ltd., which obtained its pharmaceutical business license on March 29, 2023[17] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 8.98%, up from 5.31% in the same period last year, indicating improved profitability[5] - The company experienced a 75.55% increase in accounts payable, primarily due to increased material and other payables[11] - Total operating costs amounted to ¥364,517,922.48, up 35% from ¥270,153,211.19 in Q1 2022[23] - The company reported a significant increase in sales expenses, which totaled ¥236,460,016.10, compared to ¥179,111,174.54 in the previous year, reflecting a growth of 32.1%[23] - Cash and cash equivalents at the end of Q1 2023 were ¥715,115,006.57, up from ¥694,690,170.16 at the beginning of the year, indicating a growth of 2.0%[20] Audit Status - The report for Q1 2023 was not audited[28]